Skip to main content

Research Repository

Advanced Search

Atorvastatin reduces malondialdehyde concentrations in patients with polycystic ovary syndrome

Sathyapalan, Thozhukat; Shepherd, John; Coady, Anne-Marie; Kilpatrick, Eric S.; Atkin, Stephen L.


Thozhukat Sathyapalan

John Shepherd

Anne-Marie Coady

Eric S. Kilpatrick

Stephen L. Atkin


Background: It has been shown that there is an increase in oxidative stress in polycystic ovary syndrome (PCOS). Statins are considered to have a pleiotropic effect other than their lipid-lowering effect. These effects may be mediated in part by reducing oxidative stress. Methods: This randomized, double-blind, placebo-controlled study was conducted to assess the effect of atorvastatin on serum malondialdehyde (MDA) concentrations as a marker of oxidative stress in patients with PCOS. Forty medication-naïve patients with PCOS were randomized to either atorvastatin 20 mg daily or placebo for 3 months. A 3-month extension study for both groups of patients was undertaken with metformin 1500 mg daily after completing initial 3 months of atorvastatin or placebo. Results: There was a significant decrease of MDA concentrations with atorvastatin [mean (sem)] [0.29 (0.04) vs. 0.25 (0.02) μmol/liter; P < 0.01] compared with placebo [0.28 (0.02) vs. 0.29 (0.12) μmol/liter; P = 0.52]. Three months treatment with metformin resulted in further reduction of MDA levels with atorvastatin compared with baseline [0.25 (0.02) baseline vs. 0.23 (0.03) μmol/liter for atorvastatin treated; P = 0.02]. There was also a significant correlation between the reduction in MDA with a reduction in high-sensitivity C-reactive protein (r = 0.71, P < 0.01), an increase in 25-hydroxyvitamin D (25OHD; r = −0.68, P = 0.02), and a reduction in testosterone levels (r = 0.63, P = 0.01). Multiple linear regression analysis revealed Δ25OHD, ΔC-reactive protein, and Δtestosterone were independent predictors of changes in MDA after atorvastatin treatment. No correlation was observed between the reductions in serum MDA concentrations with changes in the lipid parameters. Conclusions: Twelve weeks of atorvastatin led to a significant reduction in oxidative stress as determined by MDA concentrations among patients with polycystic ovary syndrome that was independently predicted by changes in testosterone, 25OHD, and high-sensitivity C-reactive protein.


Sathyapalan, T., Shepherd, J., Coady, A., Kilpatrick, E. S., & Atkin, S. L. (2012). Atorvastatin reduces malondialdehyde concentrations in patients with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism, 97(11), 3951-3955.

Journal Article Type Article
Acceptance Date Jul 23, 2012
Publication Date 2012-11
Print ISSN 0021-972x
Electronic ISSN 1945-7197
Publisher Oxford University Press (OUP)
Peer Reviewed Peer Reviewed
Volume 97
Issue 11
Pages 3951-3955
Keywords Clinical Biochemistry; Biochemistry; Endocrinology, Diabetes and Metabolism; Endocrinology; Biochemistry, medical
Public URL
Publisher URL